Zacks Rating on ARIAD Pharmaceuticals (ARIA)

ARIAD Pharmaceuticals (ARIA) : Zacks Investment Research ranks ARIAD Pharmaceuticals (ARIA) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 4 research analysts is 2, which indicates as a Buy.

ARIAD Pharmaceuticals (ARIA) : The consensus price target for ARIAD Pharmaceuticals (ARIA) is $11 for the short term with a standard deviation of $1.83. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $13, however, the pessimist price target for the company is $9.


Shares of Ariad Pharmaceuticals Inc. rose by 0.47% in the last five trading days and 29.27% for the last 4 weeks. Ariad Pharmaceuticals Inc. is up 33% in the last 3-month period. Year-to-Date the stock performance stands at 69.6%. ARIAD Pharmaceuticals (NASDAQ:ARIA): stock turned positive on Tuesday. Though the stock opened at $10.58, the bulls momentum made the stock top out at $10.66 level for the day. The stock recorded a low of $10.48 and closed the trading day at $10.6, in the green by 0.38%. The total traded volume for the day was 2,634,953. The stock had closed at $10.56 in the previous days trading.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.